Cite
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
MLA
Nitz, Ulrike, et al. “De-Escalated Neoadjuvant Pertuzumab plus Trastuzumab Therapy with or without Weekly Paclitaxel in HER2-Positive, Hormone Receptor-Negative, Early Breast Cancer (WSG-ADAPT-HER2+/HR-): Survival Outcomes from a Multicentre, Open-Label, Randomised, Phase 2 Trial.” Lancet Oncology, vol. 23, no. 5, May 2022, pp. 625–35. EBSCOhost, https://doi.org/10.1016/S1470-2045(22)00159-0.
APA
Nitz, U., Gluz, O., Graeser, M., Christgen, M., Kuemmel, S., Grischke, E.-M., Braun, M., Augustin, D., Potenberg, J., Krauss, K., Schumacher, C., Forstbauer, H., Reimer, T., Stefek, A., Fischer, H. H., Pelz, E., zu Eulenburg, C., Kates, R., Wuerstlein, R., & Kreipe, H. H. (2022). De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, 23(5), 625–635. https://doi.org/10.1016/S1470-2045(22)00159-0
Chicago
Nitz, Ulrike, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Michael Braun, et al. 2022. “De-Escalated Neoadjuvant Pertuzumab plus Trastuzumab Therapy with or without Weekly Paclitaxel in HER2-Positive, Hormone Receptor-Negative, Early Breast Cancer (WSG-ADAPT-HER2+/HR-): Survival Outcomes from a Multicentre, Open-Label, Randomised, Phase 2 Trial.” Lancet Oncology 23 (5): 625–35. doi:10.1016/S1470-2045(22)00159-0.